MedTrace Logo

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

NCT02757989 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2024-08-02

No results posted yet for this study

Summary

Comparison of survival in patients with or without a matched donor at 36 months

Conditions

Interventions

OTHER

transplantation

allogeneic hematopoietic stem cell transplantation in patients with donor

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Neovii Biotech

    collaborator INDUSTRY

  • Groupe Francophone des Myelodysplasies

    lead OTHER

Principal Investigators

  • Marie Robin, MD · Saint-Louis Hospital, Paris, France

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2024-06-07
Completion
2024-06-07

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02757989 on ClinicalTrials.gov